Stockreport

Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference

Turn Therapeutics Inc.  (TTRX) 
PDF Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026Appointment of Martin Dewhu [Read more]